Molecular predictive and prognostic markers in non-small-cell lung cancer

被引:173
作者
Coate, Linda E. [1 ]
John, Thomas [1 ]
Tsao, Ming-Sound [2 ]
Shepherd, Frances A. [1 ]
机构
[1] Princess Margaret Hosp, Dept Med Oncol & Hematol, Univ Hlth Network, Toronto, ON M5G 2M9, Canada
[2] Princess Margaret Hosp, Dept Pathol, Univ Hlth Network, Toronto, ON M5G 2M9, Canada
关键词
GROWTH-FACTOR RECEPTOR; III BETA-TUBULIN; VINORELBINE PLUS CISPLATIN; MESSENGER-RNA EXPRESSION; GENE COPY NUMBER; ADJUVANT CHEMOTHERAPY; ERCC1; EXPRESSION; EXCISION-REPAIR; FACTOR-ALPHA; TUMOR-CELLS;
D O I
10.1016/S1470-2045(09)70155-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer death in the developed world. Platinum-based chemotherapy is the therapeutic foundation of treatment both in the metastatic and adjuvant setting and targeted therapies are entering standard treatment paradigms. However, many patients do not obtain benefit from cytotoxic agents or newer targeted therapies, but are still exposed to their toxic effects. Reliable biomarkers to select treatments for patients most likely to obtain benefit have, therefore, been an important focus for many research groups. In this paper, we review current predictive and prognostic biomarkers in NSCLC. We assess their potential clinical use and explore recent data pertaining to genome-wide approaches for treatment selection in NSCLC.
引用
收藏
页码:1001 / 1010
页数:10
相关论文
共 57 条
[1]  
Altaha R, 2004, INT J MOL MED, V14, P959
[2]   Comparison of the dako EGFR pharmDx kit and zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma [J].
Buckley, Anne F. ;
Kakar, Sanjay .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (03) :305-309
[3]  
Burke L, 2005, CLIN CANCER RES, V11, P232
[4]  
COBO SR M, 2008, P AM SOC CLIN ONCO S, V26
[5]   Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study [J].
Crino, Lucio ;
Cappuzzo, Federico ;
Zatloukal, Petr ;
Reck, Martin ;
Pesek, Milos ;
Thompson, Joyce C. ;
Ford, Hugo E. R. ;
Hirsch, Fred R. ;
Varella-Garcia, Marileila ;
Ghiorghiu, Serban ;
Duffield, Emma L. ;
Armour, Alison A. ;
Speake, Georgina ;
Cullen, Michael .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4253-4260
[6]  
DOUILLARD J, 2008, P AM SOC CLIN ONCO S, V26
[7]   Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial [J].
Douillard, Jean-Yves ;
Rosell, Rafael ;
De Lena, Mario ;
Carpagnano, Francesco ;
Ramlau, Rodryg ;
Gonzales-Larriba, Jose Luis ;
Grodzki, Tornasz ;
Pereira, Jose Rodrigues ;
Le Groumellec, Alain ;
Lorusso, Vito ;
Clary, Claude ;
Torres, Antonio J. ;
Dahabreh, Jabrail ;
Souquet, Pierre-Jean ;
Astudillo, Julio ;
Fournel, Pierre ;
Artal-Cortes, Angel ;
Jassem, Jacek ;
Koubkova, Leona ;
His, Patricia ;
Riggi, Marcella ;
Hurteloup, Patrick .
LANCET ONCOLOGY, 2006, 7 (09) :719-727
[8]   Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].
Eberhard, DA ;
Johnson, BE ;
Amler, LC ;
Goddard, AD ;
Heldens, SL ;
Herbst, RS ;
Ince, WL ;
Jänne, PA ;
Januario, T ;
Johnson, DH ;
Klein, P ;
Miller, VA ;
Ostland, MA ;
Ramies, DA ;
Sebisanovic, D ;
Stinson, JA ;
Zhang, YR ;
Seshagiri, S ;
Hillan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909
[9]   Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer:: The international adjuvant lung cancer trial biologic program [J].
Filipits, Martin ;
Pirker, Robert ;
Dunant, Ariane ;
Lantuejoul, Sylvie ;
Schmid, Katharina ;
Huynh, Anh ;
Haddad, Vincent ;
Andre, Fabrice ;
Stahel, Rolf ;
Pignon, Jean-Pierre ;
Soria, Jean-Charles ;
Popper, Helmut H. ;
Le Chevalier, Thierry ;
Brambilla, Elisabeth .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2735-2740
[10]  
Fontanini G, 1998, CLIN CANCER RES, V4, P241